NCT01277991已完成1 期
Phase 1, Open-label, Randomized, Single-dose, 2-treatment, 2-period, Crossover, Bioequivalence Study Comparing Phase 2b 1 Mg And 5 Mg Tablet Formulations Of Cp-690,550 Under Fasted Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- Pfizer
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- PK parameters: AUCinf, AUClast and Cmax of CP-690,550
研究概览
简要总结
In this study, a 5 mg dose of CP-690,550 will be given to study subjects on two separate occasions using one of two different strength tablets each time. The amount of CP-690,550 available in the blood following administration of each tablet will be measured and compared. The overall aim of the study is to establish that a similar amount of CP-690,550 is absorbed into the blood following administration of the same dose of each different strength tablet .
详细描述
This is a bioequivalence study for CP-690,550.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 盲法
- None
入排标准
- 年龄范围
- 21 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy male and/or female (non-childbearing potential) subjects between the ages of 21 and 55 years, inclusive.
- •Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >45 kg (99 lbs).
- •No evidence of active or latent or inadequately treated infection with Mycobacterium tuberculosis (TB).
排除标准
- •Subjects with evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- •Personal or family history of hereditary immunodeficiency (eg, severe - Evidence of any clinically significant illness, medical condition, or disease.
- •Evidence or history of any clinically significant infections within the past 3 months.
- •Use of tobacco- or nicotine-containing products in excess of the equivalent of 5 cigarettes per day.
研究组 & 干预措施
Sequence 2
Experimental
干预措施: Treatment A (Drug)
Sequence 2
Experimental
干预措施: Treatment B (Drug)
Sequence 1
Experimental
干预措施: Treatment A (Drug)
Sequence 1
Experimental
干预措施: Treatment B (Drug)
结局指标
主要结局
PK parameters: AUCinf, AUClast and Cmax of CP-690,550
时间窗: PK blood samples out to 24 hours post dose in each period
次要结局
- Safety: vital signs(Prior to dosing in each period and at 24 hours post last dose in Period 2)
- PK parameters: Tmax, AUCt and half-life of CP-690,550(Derived from PK blood samples out to 24 hours post dose in each period)
- Safety: laboratory tests(Pre-dose on Day 0 for Period 1 and at 24 hours post last dose in each period)
- Safety: adverse event reporting(Throughout study)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study To Estimate The Amount Of CP-690,550 (Study Drug) That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of CP-690,550 In Tablet FormHealthyNCT01143805Pfizer12
已完成
2 期
Three Dose Levels of CP-690,550 Monotherapy Versus Placebo, Administered Orally Twice Daily (BID) for 6 WeeksRheumatoid ArthritisNCT00147498Pfizer264
已完成
2 期
A 6-Month Study Of CP-690,550 Versus Tacrolimus In Kidney Transplant PatientsKidney TransplantationNCT00106639Pfizer61
已完成
1 期
Pharmacokinetics And Dialysability Of CP-690,550 In Subjects With End-Stage Renal DiseaseEnd-Stage Renal DiseaseHemodialysisNCT01710020Pfizer12
已完成
1 期
A Prospective, Randomized, Placebo and Active Comparator Controlled Study of CP-690,550 in Subjects With Dry Eye.Dry Eye SyndromesNCT00784719Pfizer327